The status quo was pretty good for the FDA. Lily and Novo Nordisk still saw major stock price rises. Patients had super cheap drug options for something that would free up lots of money for non-medical spending in the economy. Why does an administration ruling via EO not keep the compounding loophole? It aligns with their goals. IMO, the compounders need to turn this into a media sound bite sized win for politicians. Because it certainly doesn’t make any scientific or objective medical sense to cease the compounding.